An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

A study published in Scientific Reports found that cannabidiol (CBD) disrupts lipid metabolism and induces apoptosis in ...

oxygen − dependent on its exposure duration − affects NSC expansion by regulating cell cycle length. Of note, already an exposure to atmospheric oxygen levels for a few hours dramatically shifts NSCs ...

A study published by the Journal of Traditional and Complementary Medicine and e-published by the U.S. National Library of Medicine highlights cannabidiol’s (CBD) potential as a therapeutic option for ...

Bayer’s Parkinson’s disease cell therapy is moving into late-stage testing, with the upcoming trial set to be the first registrational phase 3 study for an investigational allogeneic cell ...

17, 2024 — Using neural stem cells could help treat spinal injuries once thought to be untreatable -- a new phase 1 trial has determined this approach is ... Dec. 13, 2024 — Intermittent ...

The candidate, dubbed SIM0500, targets GPRC5D, BCMA and CD3 and is already in phase 1 trials for multiple myeloma in the U.S. and China. It’s not AbbVie’s first foray into T-cell engager ...

The company is also developing rese-cel for several other autoimmune conditions where B-cells play a major role, including myasthenia gravis, lupus, and systemic sclerosis. Phase 1/2 trials are ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in patients with extensive-stage small cell lung cancer and Merkel cell ...